RT Journal Article
SR Electronic
T1 Launching a saliva-based SARS-CoV-2 surveillance testing program on a university campus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.24.21250385
DO 10.1101/2021.01.24.21250385
A1 Alexander J. Ehrenberg
A1 Erica A. Moehle
A1 Cara E. Brook
A1 Andrew H. Doudna Cate
A1 Lea B. Witkowsky
A1 Rohan Sachdeva
A1 Ariana Hirsh
A1 Kerrie Barry
A1 Jennifer R. Hamilton
A1 Enrique Lin-Shiao
A1 Shana McDevitt
A1 Luis Valentin-Alvarado
A1 Kaitlyn N. Letourneau
A1 Lauren Hunter
A1 Amanda Keller
A1 Kathleen Pestal
A1 Phillip A. Frankino
A1 Andrew Murley
A1 Divya Nandakumar
A1 Elizabeth C. Stahl
A1 Connor A. Tsuchida
A1 Holly K. Gildea
A1 Andrew G. Murdock
A1 Megan L. Hochstrasser
A1 Elizabeth O’Brien
A1 Alison Ciling
A1 Alexandra Tsitsiklis
A1 Kurtresha Worden
A1 Claire Dugast-Darzacq
A1 Stephanie G. Hays
A1 Colin C. Barber
A1 Riley McGarrigle
A1 Emily Lam
A1 David Ensminger
A1 Lucie Bardet
A1 Carolyn Sherry
A1 the IGI SARS-CoV-2 Testing consortium
A1 Anna Harte
A1 Guy Nicolette
A1 Petros Giannikopoulos
A1 Dirk Hockemeyer
A1 Maya Petersen
A1 Fyodor D. Urnov
A1 Bradley R. Ringeisen
A1 Mike Boots
A1 Jennifer A. Doudna
YR 2021
UL http://medrxiv.org/content/early/2021/01/30/2021.01.24.21250385.abstract
AB Regular surveillance testing of asymptomatic individuals for SARS-CoV-2 has played a vital role in SARS-CoV-2 outbreak prevention on college and university campuses. Here we describe the voluntary saliva testing program instituted at the University of California, Berkeley during an early period of the SARS-CoV-2 pandemic in 2020. The program was administered as a research study ahead of clinical implementation, enabling us to launch surveillance testing while continuing to optimize the assay. Results of both the testing protocol itself and the study participants’ experience show how the program succeeded in providing routine, robust testing capable of contributing to outbreak prevention within a campus community and offer strategies for encouraging participation and a sense of civic responsibility.Competing Interest StatementThe Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences, and Inari. J.A.D. is a Director at Johnson & Johnson and has research projects sponsored by Biogen, Pfizer, AppleTree Partners, and Roche. F.D.U. is a co-founder of Tune Therapeutics. P.G. is a co-founder and Director at NewCo Health. P.G. is the CLIA Laboratory Director for Coral Genomics and 3DMed. The other authors declare no competing interests.Funding StatementWe thank the Packard Foundation, the Curci Foundation, the Julia Burke Foundation, and other anonymous donors for their support of IGI FAST. We additionally thank the University of California, Berkeley for their financial support of IGI FAST. A.J.E. is a graduate research fellow at the Greater Good Science Center at the University of California, Berkeley. J.R.H. is a Fellow of The Jane Coffin Childs Memorial Fund for Medical Research. A.M. is a fellow of the Damon Runyon Cancer Research Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of California, Berkeley Committee for Protection of Human Subjects IRB #2020-05-13336All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in this article and the supplementary files are available upon request to the corresponding authors.